Ferring partner presents positive phase III result of lumbar disc herniation treatment
Seikagaku Corporation is expecting to work toward a US submission while Ferring Pharmaceuticals prepares commercialization.
by christopher due karlsson, translated by daniel pedersen
Swiss pharmaceutical firm Ferring Pharmaceuticals and its Japanese partner, Seikagaku Corporation, report positive results from a phase III clinical study of a treatment candidate for lumbar disc herniation, called SI-6603.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ferring closes research institute, fires staff
For subscribers
